Beside B-cell lymphomas, where MyD88 activation is a direct promoter of carcinogenesis, dysregulation of MyD88 can have direct effects on tumour progression or indirect effects on the immune microenvironment of the tumour [124]. Here, MYD88 is linked to B-cell non-Hodgkin lymphoma.